Ert Pompe denied as non-formulary by AmeriHealth Caritas?

Confirmed enzyme assay + genetic testing. Specialist Rx (geneticist or metabolic).

EPSDT for under-21 overrides state PDL limits. Orphan Drug Act + FDA approval rebut 'experimental' label. Site-of-care: home infusion appropriate for stable patients per manufacturer REMS.

## Why AmeriHealth Caritas Denies ERT for Pompe Disease as Non-Formulary

AmeriHealth Caritas — primarily a Medicaid managed care organization — administers drug coverage through state-specific formularies. Enzyme replacement therapies for Pompe disease are high-cost biologics that may require prior authorization, may be placed on a specialty or restricted tier, or may not appear on the plan's standard formulary. A non-formulary denial for ERT in Pompe disease does not reflect a clinical judgment that the drug is inappropriate — it reflects formulary-tier placement. For a drug that treats a rare, progressive disease with no therapeutic alternatives, non-formulary denials are regularly overturned through exception processes.

For Medicaid enrollees, there is an additional consideration: states have Medicaid formulary requirements, and ERT for an FDA-approved indication in a rare disease may be covered regardless of tier placement under federal Medicaid law, which prohibits states from excluding coverage for medical necessity in certain categories. Your state's Medicaid program rules are relevant here.

## Federal and State Appeal Rights

For Medicaid enrollees, the appeal process runs through AmeriHealth Caritas's internal grievance and appeal system AND the state Medicaid agency's state fair hearing process. You have the right to request a state fair hearing at any point after an adverse determination, and this right runs concurrently with the internal appeal. For any commercial AmeriHealth Caritas plan, ACA Section 2719 and ERISA Section 503 apply. External review by an IRO is available for commercial plans after internal exhaustion, within approximately 4 months of the denial. Expedited review is appropriate for patients with active disease progression.

## Appeal Process and Timeline

1. Formulary exception request — submit immediately through AmeriHealth Caritas's pharmacy or medical exception process. The prescriber must attest that no formulary-listed drug treats Pompe disease. 2. Internal appeal — if the exception is denied, file a formal appeal. For Medicaid enrollees, simultaneously request a state fair hearing. 3. Peer-to-peer review — request a call between the treating metabolic specialist and AmeriHealth Caritas's medical director. 4. State fair hearing or external review — pursue the appropriate external process based on plan type.

## Documentation to Gather

• No-alternative letter: a prescriber letter stating that no AmeriHealth Caritas formulary drug is FDA-approved for the treatment of Pompe disease, making a formulary exception medically necessary.
• Confirmed diagnosis: genetic and/or enzyme activity laboratory results confirming Pompe disease.
• Prescriber medical-necessity letter: addressing AmeriHealth Caritas's formulary exception criteria, with reference to the FDA-approved prescribing label.
• Disease severity documentation: current specialist assessments documenting functional status and rate of progression.
• State Medicaid coverage rules (for Medicaid enrollees): confirm with your state Medicaid advocacy contacts or the state Medicaid agency whether ERT for Pompe disease is subject to a mandatory coverage rule regardless of formulary placement.

## Criteria-Mapping Structure

Pull AmeriHealth Caritas's formulary exception criteria from the denial letter or the plan's published exception policy. Map: (1) Is there a formulary alternative? — confirm none exists for this indication; (2) FDA approval — cite the prescribing label; (3) Medical necessity — attach specialist assessment and prescriber letter; (4) State Medicaid requirements if applicable — cite the relevant state coverage bulletin or federal Medicaid rule. For Pompe disease with no formulary alternative, a well-documented exception request is a strong and frequently successful appeal.